![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Issues Untitled Letter to South Korea’s Ycellbio
FDA Issues Untitled Letter to South Korea’s Ycellbio
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
July 30, 2018
South Korean devicemaker Ycellbio got into hot water with the FDA for marketing its Y-PRP kit in the United States without FDA clearance and the agency issued the company an untitled letter.
The firm was advertising its Y-PRP system on its website for facilitating separating and harvesting “pure sources of concentrated platelets from a small sample of blood at the patient’s point of care,” the FDA said.
For example, the company made claims that the Y-PRP kit was a regenerative therapy that could be used for dermatology, general surgery, chronic wounds and ophthalmology applications. The FDA said the company had not submitted a premarket review application as requested for the device and was in violation of the FD&C Act.
Upcoming Events
-
21Oct